Category: BÜHLMANN Calprotectin Assay Citations

A number of the publications in the citation list describe applications that are outside of product claims thus they should be used for information only.

IBDoc Key Literature List

IBDoc® Publications View a compilation of BÜHLMANN IBDoc® calprotectin citations from a wide variety of interesting publications, studies, and posters. Find valuable highlights from each publication and see the long list of studies that have utilized our assay!   View Citations Health Canada License: 98903 US: Not available for Sale in the US.
Continue Reading

100 BÜHLMANN Calprotectin Publications

BÜHLMANN launched its first fecal calprotectin assay over 10 years ago and since then has developed into THE CALPROTECTIN COMPANY with the highest quality standards. The offerings include the FDA 510(k) cleared BÜHLMANN fCAL® ELISA, the FDA 510(k) cleared automated BÜHLMANN fCAL® turbo (in combination with CALEX® Cap fecal extraction device) for testing on most
Continue Reading

Clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc

IBDoc® Citation: ECCO 2019 Poster Walmsley et al. Poster: P630 A non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. ECCO 2019: Inflammatory Bowel Diseases 14th Congress, March 6-9, 2019, Copenhagen/Denmark. Highlights from this Poster   “Use of IBDsmart and IBDoc® in
Continue Reading

Clinical Accuracy of the BÜHLMANN fCAL® ELISA in the Differentiation of IBD from IBS

BÜHLMANN fCAL® ELISA Citation Berinstein, J. et al.  The Clinical Accuracy of the BÜHLMANN fCAL® ELISA in the Differentiation of Inflammatory Bowel Disease from Irritable Bowel Syndrome: A Multi-Center Prospective Case-Control Study.  Crohn's & Colitis 360 (2019).  DOI: https://doi.org/10.1093/crocol/otz037. [Accepted Manuscript] Highlight from this Publication “The BÜHLMANN fCAL ELISA demonstrates excellent discriminating between IBD and IBS.”
Continue Reading

The Way to Total Automation of Calprotectin Measurement in Faeces with BUHLMANN fCAL® turbo

BÜHLMANN fCAL® turbo: Schallberger, Y. et al. The Way to Total Automation of Calprotectin Measurement in Faeces with BUHLMANN fCAL® turbo. Swiss MedLab 2016, 13. – 16. June 2016. Berne, Switzerland. Poster Highlights from this Publication “ ...Combined with the CALEX® Cap extraction device the fecal calprotectin testing workflow is further simplified thus reducing hands-on-time by 70%. " Read Citation
Continue Reading

Head-to-head comparison of three stool calprotectin tests for home use

IBDoc® Citation: Haisma et al. Head-to-head comparison of three stool calprotectin tests for home use.  Plos ONE. https://doi.org/10.1371/journal.pone.0214751  April 18, 2019 Highlights from this Publication “ …We observed that 119 of 125 IBDoc readings ≥ 500 μg/g were concordant with fCAL results (95%), compared to 35% and 49% for the QuantOnCal—IDK-Calprotectin and CalproSmart—Calprotectin-ALP pairs.…” “The CalproSmart
Continue Reading

Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients

BÜHLMANN fCAL® ELISA Citation Foster, A. et al. Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn's disease patients. World J Gastroenterol. PMID: 30886509 DOI: 10.3748/wjg.v25.i10.1266. Highlight from this Publication ..."Notably, in keeping with adult IBD practice, our study shows that children should also have FC levels checked every 3 mo to ensure adequate monitoring."… Read Citation BÜHLMANN
Continue Reading

Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring

IBDoc® Citation: Wei, S. , Tung, C. et al.  Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring. Intestinal Research 2018;16(4):546-553. DOI: https://doi.org/10.5217/ir.2018.00052 PMID: 30301339 Highlights from this Publication “96% of the patients were satisfied with the home test..." “71% of patients preferred the home test method monitor
Continue Reading

Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis

IBDoc® Citation: Walsh,  A,  Kormilitzin, A et al. Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis—a Prospective Analysis, Journal of Crohn's and Colitis, jjy184, PMID: 30445625   DOI: doi.org/10.1093/ecco-jcc/jjy184  Highlights from this Publication “This is the first prospective study to use validated endoscopic and histologic indices to determine the thresholds of
Continue Reading

Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn’s disease.

BÜHLMANN fCAL® ELISA Citation Pavlidis, P. et al., 2016, Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn’s disease, Scandinavian Journal of Gastroenterology.  PMID: 27400728  DOI: 10.1080/00365521.2016.1205128 Highlight from this Publication “The ΔFCAL could act as an ‘early warning’ to consider alternatives such as dose optimisation or another biologic with a different mode of action,
Continue Reading